The impact of population aging on the mortality rate of dementia among residents in Suzhou, China, 2004–2023

Background and Objectives: Alzheimer's disease and other dementias represent some of the leading public health concerns worldwide. This study aimed to assess the global burden of Alzheimer's disease and other dementias attributable to high fasting plasma glucose in the last decades. Materials and Methods: A descriptive epidemiological study was conducted. The Global Burden of Disease (GBD) study data about deaths and Disability-Adjusted Life Years (DALYs) were used. All figures were presented as age-standardized rates (ASRs). The average annual percent change (AAPC) was computed using the Joinpoint regression analysis. Also, age-period-cohort analysis was performed. Results: A total of 2 million deaths from Alzheimer's disease and other dementias were reported worldwide in 2021, whereby the total number deaths from Alzheimer's disease and other dementias attributable to high fasting plasma glucose was 290,032 (98,900 males and 191,132 females) in 2021. The highest ASRs of burden of Alzheimer's disease and other dementias attributable to high fasting plasma glucose were found in Afghanistan, Iraq, Morocco, Qatar, and the United States of America, while the lowest ASRs were in Belarus and Mongolia. From 1990 to 2021, a significant increase (p < 0.001) was noted in ASRs of deaths and DALYs for Alzheimer's disease and other dementias attributable to high fasting plasma glucose. Looking at the GBD regions, the trends in ASRs for mortality and for DALYs of Alzheimer's disease and other dementias attributable to high fasting plasma glucose between 1990 and 2021 showed a growth 10-fold faster in High-income North America (AAPC = 2.0%, for both equally) and Central Asia (AAPC = 2.4% and AAPC = 2.5%, respectively) than in the region of High-income Asia Pacific (AAPC = 0.1% and AAPC = 0.2%, respectively). The relative risk of mortality and DALYs for Alzheimer's disease and other dementias attributable to high fasting plasma glucose demonstrated statistically significant (p < 0.0001) period and cohort effects, and net drift and local drifts. Conclusions: This study showed an increase in the global burden of Alzheimer's disease and other dementias attributable to high fasting plasma glucose in the last decades. Future successful entire-population strategies targeting high fasting plasma glucose may reduce the burden of a wide range of these diseases.

Background Despite the progress made in managing HIV, the mortality trends among the general population in the United States remain understudied. This lack of information hampers the ability to implement evidence-based interventions at community levels. Our aim was to analyze the trends in HIV-related mortality among US residents by demographic characteristics such as age, gender, race/ethnicity, urbanization, and US Census Regions. State and county-wide data for Age-Adjusted Mortality Rates (AAMR) were analyzed.Figure 1:(A) AAMR of HIV reported with gender stratification, (B) crude mortality rate reported with age groups stratification, and (C) AAMR reported with race stratification.Crude mortality for females was 1.8 (AAMR=1.8), and in the male population it was about 5.3 (AAMR=5.5). For the total population, crude mortality was found to be 3.5 (AAMR=3.4).AAPC is -4.36 in females; -4.58 in males; and -4.65% overall. AAPC was increasing above 65 years of age but decreased overall below 54 years of age.AAPC is -5.44 in Hispanics, and -4.91 in Black/African Americans (with overall highest mortality).Footnotes: AAMR = Age adjusted mortality rate; AAPC: Average Annual Percent Change; and APC: Annual Percent Change. Methods We abstracted national mortality data from the multiple cause of death files in the CDC WONDER Database. The ICD-10 codes (B20-B24) were used to identify HIV deaths from 1999-2023. Trends in age-adjusted mortality rate (AAMR) were assessed using Joinpoint regression with annual percent changes (APC). National Center for Health Statistics (NCHS) 2013 was used as Urbanization Classification Scheme for County.Figure 2:(A) AAMR reported with census-region stratification, (B) urbanization stratification, and (C) trends in top-most affected states.Crude mortality rates= Northeast: 4.5 (AAMR=4.3); Midwest: 1.7 (AAMR=1.7); South: 4.7 (AAMR=4.7); and West: 2.5 (AAMR=2.5).Crude mortality rate= Urban (large central metropolitan + large fringe metropolitan): 1.8 (AAMR=1.9); Suburban (Medium metropolitan + Small metropolitan): 2.6 (AAMR=2.6); Rural (Micropolitan + non-core = non-metropolitan): 4.4 (AAMR=4.3).States in the top 90th percentile included the District of Columbia, Florida, Maryland, Louisiana, New York, and Georgia.Footnotes: AAMR = Age adjusted mortality rate; AAPC: Average Annual Percent Change; and APC: Annual Percent Change. Results Results were expressed as annual percentage changes (APC), average annual percentage changes (AAPC), and 95% confidence intervals (CI). Between 1999 and 2023, a total of 271,568 HIV-infected patients died within the US (AAMR=3.4 per 100,000; 95% CI: 3.3-3.5). Overall mortality trends decreased at an annual rate of -4.66% (95% CI: -4.96, -4.43) from 1999-2023 across the entire population. Specifically, the mortality trends increased among males (from the year 2018-2021), age groups 65-74 and 75-84 (overall), Non-Hispanic American Indian or Alaskan natives (from 2017-2023), across all regions (during 2018-2021), and increased slightly from 2017-2019 onwards across the urbanization divide. States in the top 90th percentile included: the District of Columbia, Florida, Maryland, Louisiana, New York, and Georgia. Union County and Miami-Dade County are highly affected within the state of Florida. Maryland showed a slight increase in trend in recent years, while Mississippi showed the slowest decline overall.Figure 3:Stratification of crude and age-adjusted mortality rates (AAMR) according to demographic variable among the U.S population (from 1999-2023).† AAMR not applicable to age-groups based stratification hence we used crude rates to report mortality.*AAMR not available for urbanization (year 2021-2023) hence we imputed AAMRs from crude rates.Reference: Age standardization of death rates: implementation of the year 2000 standard - PubMed [PMID: 9796247]. Available from: https://pubmed.ncbi.nlm.nih.gov/9796247/Footnotes: AAMR = Age adjusted mortality rate; AAPC: Average Annual Percent Change; and APC: Annual Percent Change. Conclusion HIV mortality among the US population has decreased overall from 1999 to 2023, but with varying demographic and geographic trends. These trends highlight the need for enhanced public health surveillance to better understand the scope of HIV mortality and to identify high-risk demographic and regional subgroups for targeted interventions.Figure 4:(A) State-wide heat map for AAMR reported from the year 1999-2023 for HIV mortality, (B) County-wide heat map for AAMR reported from the year 1999-2023 for the state of Florida, and County-wide heat map for AAMR reported from the year 1999-2023 for the state of Pennsylvania.Crude mortality rates= District of Columbia: 27.2 (AAMR=27.5); Florida: 7.1 (AAMR=7.0); Maryland: 7.3 (AAMR=6.9); Louisiana: 6.4 (AAMR=6.5); New York: 6.7 (AAMR=6.4); Georgia: 5.9 (AAMR=5.9); and Mississippi: 5.3 (AAMR=5.5).Union County, followed by Miami-Dade are highly affected within the Florida State which ranks second after the District of Columbia.counties which are highly affected within the State of Pennsylvania include Philadelphia, Delaware, Dauphine, Lehigh and Berks County.Footnotes: AAMR = Age adjusted mortality rate. Disclosures All Authors: No reported disclosures

Trends and disparities in alzheimer's disease and anemia-related mortality in adults aged ≥ 65 years in the United States from 1999 to 2023: A CDC wonder database analysis

To analyze the dynamic changes of schistosomiasis in Poyang County of Jiangxi Province from 2004 to 2020, so as to provide insight into the development of the schistosomiasis elimination strategy. Schistosomiasis control data were captured from Poyang County from 2004 to 2020, and the epidemiological data of schistosomiasis were collected from national schistosomiasis surveillance sites in Poyang County from 2005 to 2020. The endemic status of schistosomiasis was analyzed in Poyang County from 2004 to 2020, and a Joinpoint regression analysis was performed to investigate the trends of schistosomiasis in Poyang County from 2004 to 2020. The sero-prevalence and egg-prevalence of human Schistosoma japonicum infections reduced from 24.39% (24 976/102 397) and 4.53% (259/5 721) in 2004 to 5.37% (2 421/45 100) [annual percent change (APC) = average annual percent change (AAPC) = -8.64%] and 0 (0/3 963) in 2020 (APC = AAPC = -32.07%) in Poyang County, and the trends were both significant (both P < 0.01). The sero-prevalence of S. japonicum infections reduced from 1.21% (294/24 332) in bovines in 2013 to 0.58% (35/5 999) in 2020 in Poyang County, with one turning point (AAPC = -8.20%, P > 0.05). There were no townships or villages with emerging snail habitats in Poyang County from 2004 to 2020, and there were three turning points of trend in the proportion of snail areas detected in total snail areas (AAPC = -2.30%, P > 0.01). The sero-prevalence and adjusted prevalence of S. japonicum infections reduced from 60.82% (742/1 220) and 10.16% (124/1 220) in local residents in 2005 to 5.73% (70/1 221) and 0 in 2020 in national schistosomiasis surveillance sites of Poyang County, and the trends for sero-prevalence (APC = AAPC = 17.47%, P < 0.01) and adjusted prevalence of S. japonicum infections (APC = AAPC = -44.92%, P < 0.01) were both statistically significant. S. japonicum infections were identified in 10 (2005) and 2 local livestock (2007), with prevalence of 10.00% (10/100) and 13.33% (2/15), respectively, and S. japonicum infections were detected in snails in 2008 and 2009; however, no positive samples of mixed O. hupensis were detected by loop-mediated isothermal amplification. The endemic situation of schistosomiasis control had remarkably reduced in Poyang County from 2004 to 2020; however, there are still challenges for consolidating schistosomiasis control achievements and even elimination of schistosomiasis.

To analyze the trends of human schistosomiasis prevalence in Hubei Province from 2004 to 2018, so as to provide the evidence for formulating the schistosomiasis elimination strategy in the province. All data pertaining to human schistosomiasis prevalence in Hubei Province were collected from 2004 to 2018, and the trends for changes in seroprevalence, egg-positive rate and prevalence of human Schistosoma japonicum infection were analyzed using a Joinpoint regression model. Both of the numbers of residents seropositive and egg-positive for S. japonicum infections appeared a tendency towards a decline in Hubei Province from 2004 to 2018, and the prevalence of human S. japonicum infections reduced from 6.85% in 2004 to 0 in 2018. Joinpoint regression analysis showed that the prevalence of human S. japonicum infections appeared an overall tendency towards a reduction in Hubei Province from 2004 to 2018 [average annual percent change (AAPC) = -24.1%, P < 0.01], and the trends for the reduction were both significant during the period from 2004 to 2006 [annual percent change (APC) = -35.1%, P < 0.01] and from 2006 to 2018 (APC = -22.1%, P < 0.01). The prevalence of human S. japonicum infections appeared a tendency towards a decline in islet (AAPC = -25.1%, P < 0.01), inner embankment (AAPC = -26.4%, P < 0.01) and hilly subtypes of schistosomiasis-endemic areas (AAPC = -32.5%, P < 0.01) of Hubei Province from 2004 to 2018, and the prevalence all appeared a tendency towards a decline during the infection control stage (from 2004 to 2008), the transmission control stage (from 2009 to 2013) and the transmission interruption stage (from 2014 to 2018) (AAPC = -28.0%, -24.4% and -63.8%, all P values < 0.01). The seroprevalence of human S. japonicum infections appeared an overall tendency towards a decline in Hubei Province from 2004 to 2018 (AAPC = -14.5%, P < 0.01), and the trends for the reduction were both significant during the period from 2004 to 2012 (APC = -8.4%, P < 0.01) and from 2012 to 2018 (APC = -22.1%, P < 0.01). In addition, the egg-positive rate of human S. japonicum infections appeared an overall tendency towards a decline in Hubei Province from 2004 to 2018 (AAPC = -30.6%, P < 0.05), and the trend for the reduction was significant during the period from 2007 to 2014 (APC = -15.5%, P < 0.01). The prevalence of human schistosomiasis appeared a tendency towards a decline in Hubei Province from 2004 to 2018, and the islet and inner embankment subtypes of endemic areas are a high priority for schistosomiasis control during the stage moving towards elimination in Hubei Province.

Chronic lymphocytic leukemia mortality among u.S adults aged ≥65: A 56-year trend analysis and demographic disparities

The current prevalence of hepatitis C virus infection and hepatitis C virus-associated mortality in Japan falls short of the World Health Organization goal of viral hepatitis elimination by 2030. We aimed to evaluate the trends in hepatitis C virus-associated mortality in Japan. This nationwide observational study used the Japanese Vital Statistics from 1998 to 2017 and included all Japanese hepatitis C virus-associated deaths (84936) of adults aged ≥40years. We calculated the crude and age-standardized mortality rates per 100000 persons by age and sex. Joinpoint regression analysis was used to identify significant changing points in trends and to estimate the annual percentage changes and the average annual percentage changes for the entire study period. The crude mortality rate per 100000 persons (annual death number) increased from 5.5 (3548) in 1998 to 7.0 (4843) in 2005 and decreased to 4.0 (3095) in 2017. By 2017, the crude mortality rates per 100000 persons among men and women had dropped to 3.6 and 4.3, respectively. The age-standardized mortality rate was higher in women than in men. The average annual percentage change was -3.8% (95% confidence interval: -5.0 to -2.5). The declining trend was more rapid in men (-4.5%, 95% confidence interval: -5.3 to -3.6) than in women (-2.7%, 95% confidence interval: -3.8 to -1.6). Trends in hepatitis C virus-associated mortality rates have declined in an accelerating manner in Japan, especially among men.

Neurological disorders represent a significant global health issue, leading to severe cognitive impairments and being a major cause of premature mortality and disability. This study aims to utilize data from the Global Burden of Disease (GBD) research website to assess the burden of neurological disorders in the Asian region and its individual countries and territory from 1990 to 2021, with the goal of providing reference for global efforts and decision-making in the prevention, treatment, and management of neurological disorders. Based on the Global Burden of Disease data, this study assessed the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of 13 neurological disorders in the Asian region from 1990 to 2021. The epidemiological characteristics of neurological disorders across these Asian regions were analyzed. Joinpoint regression analysis was employed to assess the temporal patterns of the burden of neurological disorders, and the average annual percent change (AAPC) was calculated to determine the overall trend throughout the study period. In 2021, stroke, migraine, and Alzheimer's disease and other dementias emerged as the primary contributors to neurological burden in Asia, with stroke accounting for 112.87 million disability-adjusted life years (DALYs), followed by migraine (25.4 million) and Alzheimer's disease and other dementias (20.0 million). Stroke was also the leading cause of neurological mortality (5.03 million deaths), trailed by Alzheimer's disease and other dementias (1.0 million). Stroke, migraine, and tension-type headache had the highest prevalence rates among neurological disorders, with 57.3 million, 683.5 million, and 1130.2 million. Temporal trends from 1990 to 2021 revealed a significant decline in age-standardized DALY rates for stroke (estimated annual percentage change [EAPC]: - 1.65%), though absolute DALYs increased (EAPC: 0.06%). In contrast, Alzheimer's disease and other dementias exhibited rising age-standardized (EAPC: 0.14%) and absolute DALYs (EAPC: 2.8%), while infectious neurological diseases (e.g., meningitis, tetanus) demonstrated marked reductions in burden. Sex-specific disparities were evident, with males experiencing a higher total DALY burden (84.8 million vs. 77.05 million), driven by stroke and Parkinson's disease, whereas Alzheimer's disease and other dementias and migraine disproportionately affected females. Geographically, stroke dominated Southeast Asia (67.6% of regional DALYs), while migraine contributed most substantially to West Asia (16%). Nationally, stroke ranked as the leading cause of neurological DALYs in most Asian countries, contrasting with migraine in Israel, Kuwait, Qatar, and the United Arab Emirates. Longitudinal analyses highlighted accelerated declines in stroke DALYs post- 2004 but escalating burdens for Alzheimer's disease and other dementias after 2019, reflecting divergent epidemiological trajectories. In 2021, the burden of neurological disorders in Asia remained substantial, with stroke, migraine, and Alzheimer's disease and other dementias being the top three contributors to DALYs. The study also revealed significant differences in the burden of neurological disorders across various subregions and countries in Asia, highlighting the need for enhanced international collaboration, sharing of best practices, provision of technical support, and optimization of healthcare resource allocation.

Trends in thromboembolism-related mortality among patients with hematologic malignancies in the u.S., 1999–2023: A CDC wonder analysis

e15648 Background: Iron deficiency anemia (IDA) is the most common extra intestinal symptom in patients with colorectal cancer (CRC). IDA is also linked to a decreased long term overall survival rate and disease-free survival rate in CRC patients. The prevalence of CRC and IDA is increasing in the United States (US). However, population-level data for mortality trends related to CRC and IDA are limited. This study aims to assess these mortality trends among adults in the US, stratified by sex, race, urbanisation, and age group. Methods: We queried the CDC-WONDER database for multiple cause of death data of adults aged ≥25 years. International Classification of Diseases (ICD 10) codes C18, C19, and C20 for CRC and D50.0, D50.1, D50.8, D50.9 for IDA were used to extract mortality data. Crude mortality rates (CMR) and age-adjusted mortality rates (AAMRs) per 100,000 individuals were computed. Joinpoint regression analysis was used to determine the annual percent changes (APCs) with a 95% confidence interval (CI). Average annual percentage changes (AAPCs) were computed as weighted average of APCs. Results: From 1999 to 2022, there were 3,192 deaths related to CRC and IDA among adults aged over 25 years in the US. The AAMR was 0.05 in 1999, increasing to 0.09 in 2020 and 0.10 in 2022. The AAMR showed a decreasing initial trend from 1999 to 2012, with an APC of -3.65, followed by a steep increase through 2022 (APC: 11.67). The AAPC for the entire study period indicated a significant increasing trend (AAPC: 2.74). The AAMR for males (0.06) was greater than that for females (0.05) from 1999 to 2020, but the reverse was true from 2021 to 2022 (AAMR male: 0.093; female: 0.095). Among age groups, individuals aged 75-84 and above 85 both showed significant declines followed by sharp rises in CMR. The South and Midwest regions exhibited a recent significant increase in AAMR, although that for the South was considerably stable since 2018. From 1999 to 2020, rural areas (0.07) exhibited a consistently greater AAMR than urban areas (0.05), despite the majority of deaths (75%) occurring in urban areas. Mortality data stratified by urbanisation was unavailable for 2021 and 2022. Conclusions: This analysis highlights the significant relationship between IDA and CRC mortality, revealing alarming trends of increasing deaths since 2012, particularly among younger adults and underserved populations. While advancements in CRC screening and treatment have improved outcomes, disparities persist, amplified by limited healthcare access, socioeconomic barriers, and the COVID-19 pandemic's disruption of care. Early diagnosis and integrated management of IDA within CRC treatment protocols, alongside targeted public health efforts, are vital to addressing these inequities and improving survival rates, particularly in high-risk groups.

IntroductionPremature birth is associated with significant morbidity and mortality. Risk increases with younger gestational age. The ICD-10-CM code classifies extremely immature neonates as being born at less than 28 weeks gestation. Antenatal and neonatal interventions have improved outcomes overall. This study evaluates trends in extreme prematurity related mortality to determine if outcomes are evenly distributed among demographic groups, including pre and post COVID data.MethodsThe CDC WONDER database was utilized to gather data on extreme immaturity related mortality in infants <1 year old from 1999 to 2023. Joinpoint regression was subsequently utilized for data analysis, analyzing crude mortality rate (CMR), annual percent change (APC), and average annual percent change (AAPC), stratifying data by sex, race, region, and urban vs. rural locality.ResultsExtreme immaturity resulted in 92,917 deaths among neonates in their first year of life from 1999 to 2023. Overall CMR significantly decreased across the study period [AAPC −1.14* 95% CI (−1.45, −0.83)], with both female and male neonates experiencing a significant decrease in CMR [AAPC −1.32* 95% CI [−1.63, −1.06] and AAPC −1.10* 95% CI [−1.57, −0.68] respectively]. Black or African American neonates had a higher CMR than all other racial and ethnic groups. Of all the racial and ethnic groups, CMR significantly decreased only for Black or African American and White neonates [AAPC −1.98* 95% CI [−2.62, −1.46] and AAPC −1.12* 95% CI [−1.42, −0.82] respectively]. All US regions experienced significant declines in CMR except for the West [AAPC −0.72 95% CI (−1.32, 0.19)]. CMR decreased in urban localities but did not decrease in rural localities [AAPC −0.93* 95% CI [−1.24, −0.59] vs. AAPC 0.12 95% CI [−0.51, 0.96]].ConclusionsWhile medical advancements have improved outcomes for neonates born extremely premature, these outcomes are not evenly distributed amongst demographic groups in the United States. There was no large change in trends associated with the COVID-19 pandemic.

Disparities and reversal of declines: A 22-year analysis of mortality trends in patients with concurrent anemia and heart failure in the United States (1999–2020)

Trends and disparities in atrial fibrillation and anemia-related mortality in adults aged ≥ 25 years in the United States from 1999 to 2023: A CDC wonder database analysis

Background: Colorectal cancer (CRC) is the third leading cause of death in Georgia. There remain significantly higher CRC mortality rates in the five public health regions of Georgia (Clayton, West Central, East Central, Southeast, and Northeast regions) in comparison to the rates in the State of Georgia. However, studies that examined temporal trends in CRC mortality rates in small geographic regions are still limited. The aim of this study was to analyze the time trends in mortality due to CRC within five regions of Georgia, stratified by age groups to assess any changes in mortality trends for the period 1975 -2018. Methods: Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Mortality - All COD, Aggregated with County, Total U.S. were used to select 1975-2018 CRC mortality data. We conducted Joinpoint regression analyses of the trends in age-adjusted mortality rates (ADMRs) due to CRC, stratified by the five regions of Georgia. Age differences in mortality were also examined. The average annual percent change (AAPC) and annual percent change (APC) with confidence intervals of 95% were calculated. Results: A total of 12,972 deaths from CRC were reported in these five regions during the period 1975-2018. The ADMR of CRC were 24.4, 24.9, 23.4, 22.7, and 25.7 per 100,000 in Clayton, East Central, Southeast, Northeast, and West Central regions, respectively. The mortality rates for CRC decreased from 1975 to 2018 in Clayton, Northeast, and Southeast regions (AAPC: -1.7% to -3.4%, p-value&amp;lt;0.05). One Joinpoint trend found a significant reduction in mortality in the East Central (1984-2018) (APC: -4.1%, p-value&amp;lt;0.001) and West Central (1981-2018) regions (APC: -3.2%, p-value=0.003). When examining age differences, patients aged 75 years or older had a significant decrease in mortality from 1975 to 2018 except in the East Central region (AAPC: -2.4% to -4.5%, p-value&amp;lt;0.05). In the East Central region, one Joinpoint demonstrated a significant decrease in mortality during 1987-2018 for the 60-74 age group and during 1984 -2018 for 75+ age group (APC: -5.1% &amp; -6.1%, respectively; both p-value&amp;lt;0.05). Reduced mortality rates were also found from 1984 to 2018 in the 60-74 age group in the Northeast region (APC: -4.3%, p-value&amp;lt;0.001). However, Northeast Georgians aged 15-59 years demonstrated a non-significant trend for increase in mortality from 1975 to 2018 (AAPC: 2.1%, p-value=0.181). Conclusion: The regional burden of colorectal cancer varied across the five regions of Georgia with CRC mortality rates decreased significantly in the Clayton, Northeast, and Southeast regions. Although reduced mortality rates were found in older patients in most regions, younger patients living in Northeast regions demonstrated a slight increase in mortality. Increased CRC risk awareness, culturally tailored prevention strategies through timely CRC screening uptake, and improved access to cancer treatment are extremely important to reduce the CRC burden, especially in the most affected regions in Georgia. Citation Format: Meng-Han Tsai, Daramola N. Cabral, Justin X. Moore, Jorge Cortes. Temporal trends in colorectal cancer mortality in the five regions of Georgia, 1975-2018: A Joinpoint regression analyses [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr B143.

Breast cancer is a leading cause of morbidity and mortality among women worldwide. This study aims to analyze the trends in breast cancer incidence, mortality, and disability-adjusted life years (DALYs) across different age groups from 1990 to 2021, and to project the mortality rate for the next decade. Global breast cancer data were analyzed, focusing on three distinct age groups: 15-49 years, 50-69 years, and 70+ years. Joinpoint regression analysis was used to identify periods of significant changes in cancer rate trends (joinpoints). Age-specific annual percent changes (APC) and average annual percent changes (AAPC) were calculated to identify trends over time. Additionally, an autoregressive integrated moving average (ARIMA) model was employed to forecast future mortality rates. The overall incidence of breast cancer increased significantly with an AAPC of 1.6% from 1990 to 2021. The highest increase was observed in the 15-49 years age group (AAPC: 1.3%), while the 70+ years age group showed the lowest increase (AAPC: 0.2%). Mortality rates exhibited a complex pattern, with a modest overall increase (AAPC: 0.8%), a slight increase in the 15-49 years age group (AAPC: 0.4%), and decreases in both 50 and 69 years (AAPC: -0.4%) and 70+ years age groups (AAPC: -0.3%). DALY rates increased slightly overall (AAPC: 0.7%), primarily driven by the 15-49 years age group (AAPC: 0.4%), while the older age groups showed a declining trend (AAPC: -0.4%). Incidence rates are rising across all age groups, with the highest increase observed among younger women (15-49 years). In contrast, older age groups (50 + years) are experiencing improvements in mortality and DALYs. These findings underscore the need for targeted public health interventions, enhanced screening practices, and ongoing advancements in breast cancer treatment to address the evolving burden of this disease across different age groups.